ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors.
2 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 119 papers.
0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
Expanded Access to ABC-108, A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced,Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
Who cites it
119 citing papers in PubMed, 160 citations in OpenAlex.
- Phase II Trial of Opaganib Addition in Metastatic Castration-Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide.Cancer medicine · 2026Trial
- Research progress on the role of host factors in Chikungunya virus infection and intervention strategies.Virulence · 2026Review
- Metabolites and cancer metastasis.Oncogene · 2026Review
- Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics.Biomarker research · 2026Review
- Sphingolipid Metabolism in Obesity: Bidirectional Regulation and Comparative Perspectives on Plant Sphingolipids.Nutrients · 2026Review
- Targeting Tumor-derived Sphingosine Kinase 2 Unleashes Antitumor Immunity and Improves Survival of Mice with Group 3 Medulloblastoma.bioRxiv : the preprint server for biology · 2026Article
- Sphingosine-1-Phosphate Promotes FOS Activation in Osteosarcoma Under Tumor Acidosis.Acta physiologica (Oxford, England) · 2026Article
- Review
- Targeting cell membrane sphingolipids: a novel ceramide analog CeY-B1 inhibits migration and invasion in cervical cancer cells.Journal of translational medicine · 2026Article
- Review
- Opaganib Protects Against High-Fat Diet-Induced Hypercholesterolemia and Liver Steatosis in Mice.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Lipid metabolic reprogramming in colorectal cancer: Insights to mechanisms and therapeutics.World journal of gastrointestinal oncology · 2025Review
- Ceramide-Induced Metabolic Stress Depletes Fumarate and Drives Mitophagy to Mediate Tumor Suppression.Cancer research · 2025Article
- A Review Discussing Synthesis and Translational Studies of Medicinal Agents Targeting Sphingolipid Pathways.Biomolecules · 2025Review
- Lipids: Driving Forces in the Underlying Biology of Carcinogenesis.ACS pharmacology & translational science · 2025Review
- Lipid Metabolism Reprogramming in Tumor-Associated Macrophages Modulates Their Function in Primary Liver Cancers.Cancers · 2025Review
- Drug Resistance: The Role of Sphingolipid Metabolism.International journal of molecular sciences · 2025Review
- Discovery of Sphingosine Kinase Inhibition by Modified Quinoline-5,8-Diones.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Opaganib Promotes Weight Loss and Suppresses High-Fat Diet-Induced Obesity and Glucose Intolerance.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Radiation-induced intestinal injury: from molecular mechanisms to clinical translation.Oncology reviews · 2025Review
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Carolyn D BrittenDivision of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Elizabeth Garrett-MayerDepartment of Population Sciences, Medical University of South Carolina, Charleston, South Carolina.
Steven H ChinDivision of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Keisuke ShiraiDivision of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Besim OgretmenDepartment of Biochemistry & Molecular Biology, Medical University of South Carolina, Charleston, South Carolina.
Tricia A BentzHollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
Alan BrisendineHollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
Kate AndertonHollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
Susan L CusackApogee Biotechnology Corporation, Hummelstown, Pennsylvania.
Lynn W MainesApogee Biotechnology Corporation, Hummelstown, Pennsylvania.
Yan ZhuangApogee Biotechnology Corporation, Hummelstown, Pennsylvania.
Charles D SmithApogee Biotechnology Corporation, Hummelstown, Pennsylvania. cdsmith@apogee-biotech.com.
Melanie B ThomasDivision of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
Medical University of South Carolina · USApogee Biotechnology (United States) · USMUSC Hollings Cancer Center · US
Funding
Translational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7MSouth Carolina Clinical & Translational Research Institute (SCTR)UL1TR000062 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2012 to 2014
$9.4MProject 3: Targeting SK2/S1P Signaling for the Regulation of c-Myc and Tumor SuppressionP01CA203628 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BIELAWSKA, ALICJA · 2016 to 2021
$8.9MSphingosine Kinase as a Target for Cancer TherapyR01CA122226 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI SMITH, CHARLES D. · 2007 to 2011
$1.4MNovel Inhibitors of Human N-MyristoyltransferaseR43CA102853 · NCI · APOGEE BIOTECHNOLOGY CORPORATION · PI ZHUANG, YAN · 2003 to 2004
$492kPhase 1 Study of ABC294640 for the Treatment of Pancreatic CancerR01FD004102 · FDA · APOGEE BIOTECHNOLOGY CORPORATION · PI MAINES, LYNN W · 2012 to 2012
$200kFDA HHS R01 FD004102NCATS NIH HHS UL1 TR000062NCI NIH HHS P01 CA203628NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA122226NCI NIH HHS R43 CA102853
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdamantaneAdultAgedDose-Response Relationship, DrugFatigueFemaleHumansMaleMiddle AgedNauseaNeoplasmsPhosphotransferases (Alcohol Group Acceptor)PyridinesSphingosine KinaseTreatment OutcomeVomiting3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amideAdamantanePhosphotransferases (Alcohol Group Acceptor)PyridinesSphingosine Kinasesphingosine kinase 2, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03377179ClinicalTrials.gov
NCT03414489ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.